MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
CANNANNEW REPORT

Bascom Palmer Eye Institute ranked the #1 eye hospital in the United States for 20 years in a row by U.S. News & World Report BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that it has entered into a material transfer agreement (MTA) with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1® as a potential treatment for traumatic optic neuropathy (TON). The project is fully funded by Bascom Palmer Eye Institute. TON is a condition caused by injury to the optic nerve, resulting in partial or complete vision loss. Visual impairment is usually caused by blunt force trauma to the head. The reported incidence of TON ranges from 1.5% to 4% following head trauma1, and each year an estimated 2.8 million Americans sustain a traumatic brain injury2. Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD, commented, “We are excited about this agreement with our country’s top eye institute to test our lead drug candidate MYMD-1 in ophthalmology. Bascom Palmer is virtually unmatched as a world leader in vision research and care and their interest in MYMD-1 validates our belief in the potential of the drug for autoimmune and inflammatory conditions.” Dr. David Tse, M.D., FACS, Professor of Ophthalmology and the Dr. Nasser Ibrahim Al-Rashid Chair in Ophthalmology at Bascom Palmer Eye Institute commented, “Through this partnership with MYMD, we look forward to investigating the potential utility of an oral TNF-alpha inhibitor in animal models of eye-related diseases.” “Following this initial pre-clinical study, the potential exists to collaborate with Bascom Palmer on large patient studies in the future,” Dr. Chapman continued. “This collaboration reiterates MyMD’s dedication to partnering with top-tier academic institutions…

Excerpt only …
READ MORE BELOW
Source : MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.